Literature DB >> 1878592

Administration of erythropoietin to newborn rats results in diminished neutrophil production.

R D Christensen1, K W Liechty, J M Koenig, K R Schibler, R K Ohls.   

Abstract

Very high concentrations of erythropoietin (epo), in clonogenic cultures, result in reduced production of neutrophils, and fetal progenitors are more sensitive to this effect of epo than are those of adults. However, the significance of this observation is unclear because no evidence of reduced neutrophil production has been presented following administration of recombinant epo to human or animal subjects. In the present study we injected newborn rats, beginning on the first day of life, with 20, 200, or 2,000 U epo/kg body weight, and measured serum epo concentrations after 2, 8, 24, or 48 hours. After selecting a dose that resulted in serum concentrations greater than 1,000 mU/mL (a concentration that resulted in down-modulation of neutrophil production from neonatal rat progenitors in vitro) other newborn rats were treated for 3 days with that dose (1,000 U epo/kg) or a vehicle control. Administration of epo resulted in increased hematocrits (P less than .001), reticulocyte counts (P less than .001), normoblasts/femur (P less than .05), and normoblasts/spleen (P less than .001). Recipients of epo also had more erythroid colony-forming units (CFU-E) (P less than .001) and higher CFU-E tritiated thymidine suicide rates (P less than .01) than did controls. However, femurs and spleens of epo recipients contained fewer postmitotic neutrophils (femur, P less than .01; spleen, P less than .01), proliferative neutrophils (femur, P less than .01; spleen, P less than .02), granulocyte-macrophage colony-forming units (CFU-GM) (P less than .005), and lower CFU-GM tritiated thymidine suicide rates (P less than .01). Seven and nine days after twice-daily administration of 2,000 U epo/kg, blood neutrophil concentrations had diminished (P less than .05). Thus, administration of high doses of recombinant epo to newborn rats resulted in diminished neutrophil production accompanying accelerated erythropoiesis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1878592

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  6 in total

1.  Transient neutropenia may be a risk of treating preterm neonates with high doses of recombinant erythropoietin.

Authors:  G Latini; E Rosati
Journal:  Eur J Pediatr       Date:  1998-05       Impact factor: 3.183

Review 2.  Haemopoietic colony stimulating factors for preterm neonates.

Authors:  R Carr; N Modi
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1997-03       Impact factor: 5.747

Review 3.  A risk-benefit assessment of epoetin in the management of anaemia associated with cancer.

Authors:  Y Beguin
Journal:  Drug Saf       Date:  1998-10       Impact factor: 5.606

4.  Effect of lidocaine on the hematopoietic properties of recombinant human erythropoietin in the uremic rat.

Authors:  R A Kaplan; S Allen; B A Warady; U S Alon
Journal:  Pediatr Nephrol       Date:  1994-08       Impact factor: 3.714

5.  Late-onset neutropenia: defining limits of neutrophil count in very low birth weight infants.

Authors:  S Vetter-Laracy; P-R Balliu; J A Salinas; M A Duran
Journal:  J Perinatol       Date:  2013-09-12       Impact factor: 2.521

6.  Pancytopenia due to iron deficiency worsened by iron infusion: a case report.

Authors:  Apar Kishor Ganti; Nicole A Shonka; William D Haire
Journal:  J Med Case Rep       Date:  2007-12-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.